Supplement encyclopedia

QUERCETIN

Quercetin is a plant flavonoid found in fruit and vegetables and sold in dietary supplements.

Double-check the conclusions and examine the sources before choosing a supplement.

Main conclusion

Potential benefits

  • In small studies in young people, quercetin reduced muscle soreness during the first day after intense exercise. These findings are still unreliable: results differed between studies.
  • In a small study of a special form of quercetin, people with mild nose and eye complaints rated their sleep more favorably. No convincing advantage was found for the overall change in nose and eye complaints.
  • In healthy older people, a particular onion powder improved the result of one thinking test and reduced ratings of low mood and indifference. These are preliminary findings about a food product; pure quercetin was not studied in this experiment.
  • A large trial of quercetin combined with vitamins C and B3 found no clear benefit for memory or attention. There was also no convincing reduction in the duration and severity of cold complaints overall.

[1] [2] [3] [4] [5]

What was studied

  • Adults took a blend of quercetin, vitamin C and niacin (vitamin B3) for 12 weeks while memory, attention and complaints associated with cold symptoms were examined. People aged 40 and older who rated their physical fitness highly were considered separately; this was a subgroup of the same trial, not a separate experiment.
  • A phytosomal form of quercetin was studied for four weeks in 60 adults with mild nose and eye complaints. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed.
  • Muscle soreness during the first day after intense exercise was assessed in young participants. In the studies included in the review, the preparation was taken for 14 days or once three hours before exercise.
  • A particular onion powder was studied for 24 weeks in healthy older people. Performance on mental tasks and self-reported mood were assessed.

[1] [2] [3] [4] [5]

Which forms were considered

  • The studies used quercetin preparations, a special phytosomal form, a blend with vitamins C and B3, and onion powder. These are different products, so a result for one cannot be applied to all the others.
  • Quercetin forms may differ in absorption. This alone does not show which one is better for well-being.

[1] [2] [3] [4] [5]

How to obtain it from food

  • Quercetin is found in onions, kale, broccoli, apples with skin and cranberries; the table gives amounts for 100 g of raw edible foods.
  • The figures in the table are for comparing foods. They cannot be used to select a food serving equivalent to the supplement dose studied.

[1]

Effects and studied questions

How to read the certainty scale 1–4

Certainty is rated separately for each outcome. 1 is very low, 2 is low, 3 is moderate and 4 is high.

Goal or questionResultConfidenceStudiesPopulation studiedKey sources
CNS Vital Signs cognitive test resultsCommunity adults; 941 completed, 309/319/313. CNS Vital Signs cognitive domains: No significant group-by-time interaction was found for memory, attention, psychomotor speed or cognitive flexibility. Means ± SD before and after for each of the six domains are given in the results table. The formulation cannot be regarded as proven monotherapy.No significant group-by-time interaction was found for memory, attention, psychomotor speed or cognitive flexibility. Means ± SD before and after for each of the six domains are given in the results table.
3/4 ModerateModerate confidence in this trial’s results for the specified cognitive measures of the combination: the overall interaction test found no significant differences; the magnitude of possible comparative effects remains only imprecisely defined. This is not evidence of no effect or equivalence.
1one study, 941 completersThe effects of quercetin supplementation on cognitive functioning in a community sample: a randomized, placebo-controlled trial ↗Community adults; 941 completed, 309/319/313
  1. The effects of quercetin supplementation on cognitive functioning in a community sample: a randomized, placebo-controlled trial ↗
MMSE total cognitive test score, pointsHealthy older people; analysis 28/33. MMSE Sum score (score): At baseline 27.1 ± 1.5 versus 27.5 ± 1.4; change over 24 weeks 1.7 ± 1.9 versus 0.9 ± 1.7, p=0.024*; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.At baseline 27.1 ± 1.5 versus 27.5 ± 1.4; change over 24 weeks 1.7 ± 1.9 versus 0.9 ± 1.7, p=0.024*; mean ± SD.
2/4 LowLow confidence in the difference in changes in MMSE Sum score (score) for the food product studied: small groups and variability of estimates limit precision, while exclusions and multiple related comparisons create risk of bias. The observed difference does not establish practical significance. Applicability is limited to the specified products and population.
1one study, analysis 28/33The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗Healthy older people; analysis 28/33
  1. The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗
Temporal orientation (MMSE), pointsHealthy older people; analysis 28/33. MMSE Temporal orientation (score): At baseline 4.9 ± 0.3 versus 5.0 ± 0.0; change over 24 weeks 0.1 ± 0.3 versus 0.0 ± 0.2, p=0.046*; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.At baseline 4.9 ± 0.3 versus 5.0 ± 0.0; change over 24 weeks 0.1 ± 0.3 versus 0.0 ± 0.2, p=0.046*; mean ± SD.
2/4 LowLow confidence in the difference in changes in MMSE Temporal orientation (score) for the food product studied: small groups and variability of estimates limit precision, while exclusions and multiple related comparisons create risk of bias. The observed difference does not establish practical significance. Applicability is limited to the specified products and population.
1one study, analysis 28/33The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗Healthy older people; analysis 28/33
  1. The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗

The study count refers to the cited source. Reviews with overlapping trials and outcomes from one study are not added together.

Daily intake requirements and upper limits

Intake and regimens studied
ContextInformation
Intake and regimens studiedThe cognitive-task study used chewable tablets with 500 or 1000 mg quercetin per day together with vitamin C and niacin for 12 weeks. These regimens do not establish a universal dose.

The effects of quercetin supplementation on cognitive functioning in a community sample: a randomized, placebo-controlled trial ↗

Forms

Quercetin occurs in plants in different chemical forms; aglycone, glycosides and phytosomal preparations differ. Differences in absorption do not prove superiority for well-being.

Guidance for each goal

CNS Vital Signs cognitive test results3/4 ModerateRead moreCollapse
Confidence
3/4 ModerateModerate confidence in this trial’s results for the specified cognitive measures of the combination: the overall interaction test found no significant differences; the magnitude of possible comparative effects remains only imprecisely defined. This is not evidence of no effect or equivalence.

Community adults; 941 completed, 309/319/313. CNS Vital Signs cognitive domains: No significant group-by-time interaction was found for memory, attention, psychomotor speed or cognitive flexibility. Means ± SD before and after for each of the six domains are given in the results table. The formulation cannot be regarded as proven monotherapy.

Study findings. Community adults; 941 completed, 309/319/313. CNS Vital Signs cognitive domains: No significant group-by-time interaction was found for memory, attention, psychomotor speed or cognitive flexibility. Means ± SD before and after for each of the six domains are given in the results table. The formulation cannot be regarded as proven monotherapy.

Studied regimen500 or 1000 mg quercetin/dayquercetin chewable tablets; the linked study describes a combination with vitamin C and niacin
Duration and population12 weeksCommunity adults; 941 completed, 309/319/313

Comparison with placebo

MMSE total cognitive test score, points2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the difference in changes in MMSE Sum score (score) for the food product studied: small groups and variability of estimates limit precision, while exclusions and multiple related comparisons create risk of bias. The observed difference does not establish practical significance. Applicability is limited to the specified products and population.

Healthy older people; analysis 28/33. MMSE Sum score (score): At baseline 27.1 ± 1.5 versus 27.5 ± 1.4; change over 24 weeks 1.7 ± 1.9 versus 0.9 ± 1.7, p=0.024*; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Study findings. Healthy older people; analysis 28/33. MMSE Sum score (score): At baseline 27.1 ± 1.5 versus 27.5 ± 1.4; change over 24 weeks 1.7 ± 1.9 versus 0.9 ± 1.7, p=0.024*; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Studied regimen11 g/day, about 50 mg quercetin aglycone equivalentsSarasara Gold onion powder
Duration and population24 weeksHealthy older people; analysis 28/33

Comparison with white onion powder without quercetin

Temporal orientation (MMSE), points2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the difference in changes in MMSE Temporal orientation (score) for the food product studied: small groups and variability of estimates limit precision, while exclusions and multiple related comparisons create risk of bias. The observed difference does not establish practical significance. Applicability is limited to the specified products and population.

Healthy older people; analysis 28/33. MMSE Temporal orientation (score): At baseline 4.9 ± 0.3 versus 5.0 ± 0.0; change over 24 weeks 0.1 ± 0.3 versus 0.0 ± 0.2, p=0.046*; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Study findings. Healthy older people; analysis 28/33. MMSE Temporal orientation (score): At baseline 4.9 ± 0.3 versus 5.0 ± 0.0; change over 24 weeks 0.1 ± 0.3 versus 0.0 ± 0.2, p=0.046*; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Studied regimen11 g/day, about 50 mg quercetin aglycone equivalentsSarasara Gold onion powder
Duration and population24 weeksHealthy older people; analysis 28/33

Comparison with white onion powder without quercetin

Spatial orientation (MMSE), points2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the difference in changes in MMSE Spatial orientation (score) for the food product studied: small groups and variability of estimates limit precision, while exclusions and multiple related comparisons create risk of bias. A statistically non-significant difference does not prove equality of effects. Applicability is limited to the specified products and population.

Healthy older people; analysis 28/33. MMSE Spatial orientation (score): At baseline 4.4 ± 0.7 versus 4.0 ± 0.8; change over 24 weeks 0.4 ± 0.9 versus 0.6 ± 0.9, p=0.446; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Study findings. Healthy older people; analysis 28/33. MMSE Spatial orientation (score): At baseline 4.4 ± 0.7 versus 4.0 ± 0.8; change over 24 weeks 0.4 ± 0.9 versus 0.6 ± 0.9, p=0.446; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Studied regimen11 g/day, about 50 mg quercetin aglycone equivalentsSarasara Gold onion powder
Duration and population24 weeksHealthy older people; analysis 28/33

Comparison with white onion powder without quercetin

Registration (MMSE), points2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the difference in changes in MMSE Registration (score) for the food product studied: small groups and variability of estimates limit precision, while exclusions and multiple related comparisons create risk of bias. A statistically non-significant difference does not prove equality of effects. Applicability is limited to the specified products and population.

Healthy older people; analysis 28/33. MMSE Registration (score): At baseline 2.9 ± 0.6 versus 3.0 ± 0.0; change over 24 weeks 0.1 ± 0.6 versus 0.0 ± 0.0, p=0.212; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Study findings. Healthy older people; analysis 28/33. MMSE Registration (score): At baseline 2.9 ± 0.6 versus 3.0 ± 0.0; change over 24 weeks 0.1 ± 0.6 versus 0.0 ± 0.0, p=0.212; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Studied regimen11 g/day, about 50 mg quercetin aglycone equivalentsSarasara Gold onion powder
Duration and population24 weeksHealthy older people; analysis 28/33

Comparison with white onion powder without quercetin

Attention (MMSE), points2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the difference in changes in MMSE Attention (score) for the food product studied: small groups and variability of estimates limit precision, while exclusions and multiple related comparisons create risk of bias. A statistically non-significant difference does not prove equality of effects. Applicability is limited to the specified products and population.

Healthy older people; analysis 28/33. MMSE Attention (score): At baseline 4.0 ± 0.9 versus 4.2 ± 1.0; change over 24 weeks 0.6 ± 1.2 versus 0.3 ± 1.0, p=0.286; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Study findings. Healthy older people; analysis 28/33. MMSE Attention (score): At baseline 4.0 ± 0.9 versus 4.2 ± 1.0; change over 24 weeks 0.6 ± 1.2 versus 0.3 ± 1.0, p=0.286; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Studied regimen11 g/day, about 50 mg quercetin aglycone equivalentsSarasara Gold onion powder
Duration and population24 weeksHealthy older people; analysis 28/33

Comparison with white onion powder without quercetin

Recall from memory (MMSE), points2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the difference in changes in MMSE Remote memory (score) for the food product studied: small groups and variability of estimates limit precision, while exclusions and multiple related comparisons create risk of bias. A statistically non-significant difference does not prove equality of effects. Applicability is limited to the specified products and population.

Healthy older people; analysis 28/33. MMSE Remote memory (score): At baseline 2.7 ± 0.5 versus 2.8 ± 0.5; change over 24 weeks 0.3 ± 0.6 versus 0.1 ± 0.6, p=0.292; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Study findings. Healthy older people; analysis 28/33. MMSE Remote memory (score): At baseline 2.7 ± 0.5 versus 2.8 ± 0.5; change over 24 weeks 0.3 ± 0.6 versus 0.1 ± 0.6, p=0.292; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Studied regimen11 g/day, about 50 mg quercetin aglycone equivalentsSarasara Gold onion powder
Duration and population24 weeksHealthy older people; analysis 28/33

Comparison with white onion powder without quercetin

Naming two objects (MMSE), points2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison of changes in MMSE Naming two objects (score) in the food groups studied: the small sample, properties of the bounded scale, numerous measures analyzed and exclusions from analysis limit the conclusion. Naming: both groups had baseline 2.0±0.0 and Δ0.0±0.0; all observed values were at the ceiling, and p=1 does not prove equivalence in the population. Lack of statistical significance at week 24 does not prove equality or absence of an effect; the contribution of quercetin alone was not isolated.

Healthy older people; analysis 28/33. MMSE Naming two objects (score): At baseline 2.0 ± 0.0 versus 2.0 ± 0.0; change over 24 weeks 0.0 ± 0.0 versus 0.0 ± 0.0, p=1.000; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Study findings. Healthy older people; analysis 28/33. MMSE Naming two objects (score): At baseline 2.0 ± 0.0 versus 2.0 ± 0.0; change over 24 weeks 0.0 ± 0.0 versus 0.0 ± 0.0, p=1.000; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Studied regimen11 g/day, about 50 mg quercetin aglycone equivalentsSarasara Gold onion powder
Duration and population24 weeksHealthy older people; analysis 28/33

Comparison with white onion powder without quercetin

Repeating a phrase (MMSE), points2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison of changes in MMSE Repeat (score) in the food groups studied: the small sample, properties of the bounded scale, numerous measures analyzed and exclusions from analysis limit the conclusion. Repeat: the baseline difference 0.8±0.4 versus 1.0±0.0, p=0.022, pertains to baseline; p=0.275 pertains to change at week 24. Lack of statistical significance at week 24 does not prove equality or absence of an effect; the contribution of quercetin alone was not isolated.

Healthy older people; analysis 28/33. MMSE Repeat (score): At baseline 0.8 ± 0.4 versus 1.0 ± 0.0; change over 24 weeks 0.0 ± 0.4 versus −0.1 ± 0.2, p=0.275; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Study findings. Healthy older people; analysis 28/33. MMSE Repeat (score): At baseline 0.8 ± 0.4 versus 1.0 ± 0.0; change over 24 weeks 0.0 ± 0.4 versus −0.1 ± 0.2, p=0.275; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Studied regimen11 g/day, about 50 mg quercetin aglycone equivalentsSarasara Gold onion powder
Duration and population24 weeksHealthy older people; analysis 28/33

Comparison with white onion powder without quercetin

Following an instruction (MMSE), points2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison of changes in MMSE Stage command (score) in the food groups studied: the small sample, properties of the bounded scale, numerous measures analyzed and exclusions from analysis limit the conclusion. Stage command: baseline scores 2.8 and 2.6 were close to the upper limit, limiting room for improvement; observed changes were 0.1 versus 0.2. Lack of statistical significance at week 24 does not prove equality or absence of an effect; the contribution of quercetin alone was not isolated.

Healthy older people; analysis 28/33. MMSE Stage command (score): At baseline 2.8 ± 0.4 versus 2.6 ± 0.6; change over 24 weeks 0.1 ± 0.6 versus 0.2 ± 0.7, p=0.821; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Study findings. Healthy older people; analysis 28/33. MMSE Stage command (score): At baseline 2.8 ± 0.4 versus 2.6 ± 0.6; change over 24 weeks 0.1 ± 0.6 versus 0.2 ± 0.7, p=0.821; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Studied regimen11 g/day, about 50 mg quercetin aglycone equivalentsSarasara Gold onion powder
Duration and population24 weeksHealthy older people; analysis 28/33

Comparison with white onion powder without quercetin

Writing a sentence (MMSE), points2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison of changes in MMSE Writing a complete sentence (score) in the food groups studied: the small sample, properties of the bounded scale, numerous measures analyzed and exclusions from analysis limit the conclusion. Sentence writing: rounded baseline values of 1.0 in both groups indicate a ceiling limitation; nonzero SDs are retained as published. Lack of statistical significance at week 24 does not prove equality or absence of an effect; the contribution of quercetin alone was not isolated.

Healthy older people; analysis 28/33. MMSE Writing a complete sentence (score): At baseline 1.0 ± 0.2 versus 1.0 ± 0.0; change over 24 weeks 0.0 ± 0.3 versus 0.0 ± 0.2, p=0.601; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Study findings. Healthy older people; analysis 28/33. MMSE Writing a complete sentence (score): At baseline 1.0 ± 0.2 versus 1.0 ± 0.0; change over 24 weeks 0.0 ± 0.3 versus 0.0 ± 0.2, p=0.601; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Studied regimen11 g/day, about 50 mg quercetin aglycone equivalentsSarasara Gold onion powder
Duration and population24 weeksHealthy older people; analysis 28/33

Comparison with white onion powder without quercetin

Reading and following an instruction (MMSE), points2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison of changes in MMSE Reading and obey (score) in the food groups studied: the small sample, properties of the bounded scale, numerous measures analyzed and exclusions from analysis limit the conclusion. Reading and obeying: baseline values 0.9 and changes −0.1 in both groups, but the available variability does not establish equivalence. Lack of statistical significance at week 24 does not prove equality or absence of an effect; the contribution of quercetin alone was not isolated.

Healthy older people; analysis 28/33. MMSE Reading and obey (score): At baseline 0.9 ± 0.4 versus 0.9 ± 0.3; change over 24 weeks −0.1 ± 0.4 versus −0.1 ± 0.3, p=0.859; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Study findings. Healthy older people; analysis 28/33. MMSE Reading and obey (score): At baseline 0.9 ± 0.4 versus 0.9 ± 0.3; change over 24 weeks −0.1 ± 0.4 versus −0.1 ± 0.3, p=0.859; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Studied regimen11 g/day, about 50 mg quercetin aglycone equivalentsSarasara Gold onion powder
Duration and population24 weeksHealthy older people; analysis 28/33

Comparison with white onion powder without quercetin

Copying a drawing (MMSE), points2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison of changes in MMSE Copy the diagram (score) in the food groups studied: the small sample, properties of the bounded scale, numerous measures analyzed and exclusions from analysis limit the conclusion. Copying: for Δ12 weeks p=0.024, for Δ24 weeks p=0.067; these are different comparisons and the first cannot be transferred to the second. Lack of statistical significance at week 24 does not prove equality or absence of an effect; the contribution of quercetin alone was not isolated.

Healthy older people; analysis 28/33. MMSE Copy the diagram (score): At baseline 0.9 ± 0.4 versus 1.0 ± 0.2; change over 24 weeks 0.1 ± 0.4 versus −0.1 ± 0.2, p=0.067; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Study findings. Healthy older people; analysis 28/33. MMSE Copy the diagram (score): At baseline 0.9 ± 0.4 versus 1.0 ± 0.2; change over 24 weeks 0.1 ± 0.4 versus −0.1 ± 0.2, p=0.067; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Studied regimen11 g/day, about 50 mg quercetin aglycone equivalentsSarasara Gold onion powder
Duration and population24 weeksHealthy older people; analysis 28/33

Comparison with white onion powder without quercetin

CADi2 total score, points2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison of CADi2 total score (score) for the specified food products: small sample size and variability of changes limit precision, while exclusions and multiple secondary comparisons affect reliability. The active group had 9.3 versus 8.8 at baseline (p=0.014); this is a baseline difference, not a treatment effect. For Δ24 p=0.262. The data do not isolate the effect of quercetin alone.

Healthy older people; analysis 28/33. CADi2 total score (score): At baseline 9.3 ± 1.0 versus 8.8 ± 1.0; change over 24 weeks 0.0 ± 0.9 versus 0.2 ± 1.0, p=0.262; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Study findings. Healthy older people; analysis 28/33. CADi2 total score (score): At baseline 9.3 ± 1.0 versus 8.8 ± 1.0; change over 24 weeks 0.0 ± 0.9 versus 0.2 ± 1.0, p=0.262; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Studied regimen11 g/day, about 50 mg quercetin aglycone equivalentsSarasara Gold onion powder
Duration and population24 weeksHealthy older people; analysis 28/33

Comparison with white onion powder without quercetin

CADi2 completion time, seconds2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison of CADi2 total response time (s) for the specified food products: small sample size and variability of changes limit precision, while exclusions and multiple secondary comparisons affect reliability. Response time Δ12 has p=0.047 and Δ24 p=0.728; these time points and comparisons must not be conflated. Negative changes indicate shorter time, not improvement in all cognitive functions. The data do not isolate the effect of quercetin alone.

Healthy older people; analysis 28/33. CADi2 total response time (s): At baseline 98.9 ± 34.8 versus 94.5 ± 22.1; change over 24 weeks −11.9 ± 33.4 versus −7.3 ± 21.5, p=0.728; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Study findings. Healthy older people; analysis 28/33. CADi2 total response time (s): At baseline 98.9 ± 34.8 versus 94.5 ± 22.1; change over 24 weeks −11.9 ± 33.4 versus −7.3 ± 21.5, p=0.728; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Studied regimen11 g/day, about 50 mg quercetin aglycone equivalentsSarasara Gold onion powder
Duration and population24 weeksHealthy older people; analysis 28/33

Comparison with white onion powder without quercetin

Low mood (Self-rating Depression Scale, SDS), points2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison of Self-rating Depression Scale (score) for the specified food products: small sample size and variability of changes limit precision, while exclusions and multiple secondary comparisons affect reliability. The difference in SDS changes at 24 weeks has p=0.020; this is a separate mood scale in healthy older adults, not a diagnosis or proven treatment of depression. The data do not isolate the effect of quercetin alone.

Healthy older people; analysis 28/33. Self-rating Depression Scale (score): At baseline 32.5 ± 7.7 versus 33.1 ± 5.9; change over 24 weeks −2.4 ± 5.0 versus −0.1 ± 4.9, p=0.020*; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Study findings. Healthy older people; analysis 28/33. Self-rating Depression Scale (score): At baseline 32.5 ± 7.7 versus 33.1 ± 5.9; change over 24 weeks −2.4 ± 5.0 versus −0.1 ± 4.9, p=0.020*; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Studied regimen11 g/day, about 50 mg quercetin aglycone equivalentsSarasara Gold onion powder
Duration and population24 weeksHealthy older people; analysis 28/33

Comparison with white onion powder without quercetin

Apathy — indifference (Apathy Scale), points2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison of Apathy Scale (score) for the specified food products: small sample size and variability of changes limit precision, while exclusions and multiple secondary comparisons affect reliability. The difference in Apathy Scale changes at 24 weeks has p=0.021; baseline 6.4 versus 4.8 and the possible influence of baseline differences remain important. This is a separate scale, not evidence of an effect on all cognition. The data do not isolate the effect of quercetin alone.

Healthy older people; analysis 28/33. Apathy Scale (score): At baseline 6.4 ± 4.8 versus 4.8 ± 4.1; change over 24 weeks −2.6 ± 3.8 versus −0.1 ± 3.0, p=0.021*; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Study findings. Healthy older people; analysis 28/33. Apathy Scale (score): At baseline 6.4 ± 4.8 versus 4.8 ± 4.1; change over 24 weeks −2.6 ± 3.8 versus −0.1 ± 3.0, p=0.021*; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Studied regimen11 g/day, about 50 mg quercetin aglycone equivalentsSarasara Gold onion powder
Duration and population24 weeksHealthy older people; analysis 28/33

Comparison with white onion powder without quercetin

Word recall (separate test), points2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison of Verbal recall test (score) for the specified food products: small sample size and variability of changes limit precision, while exclusions and multiple secondary comparisons affect reliability. For verbal recall, group changes were 1.8 and 1.2, p=0.640; lack of significance establishes neither absence of effect nor equivalence. The data do not isolate the effect of quercetin alone.

Healthy older people; analysis 28/33. Verbal recall test (score): At baseline 9.6 ± 2.5 versus 10.2 ± 1.8; change over 24 weeks 1.8 ± 3.1 versus 1.2 ± 2.2, p=0.640; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Study findings. Healthy older people; analysis 28/33. Verbal recall test (score): At baseline 9.6 ± 2.5 versus 10.2 ± 1.8; change over 24 weeks 1.8 ± 3.1 versus 1.2 ± 2.2, p=0.640; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Studied regimen11 g/day, about 50 mg quercetin aglycone equivalentsSarasara Gold onion powder
Duration and population24 weeksHealthy older people; analysis 28/33

Comparison with white onion powder without quercetin

muscle soreness 0–24 hours after exercise1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowVery low confidence in the pooled muscle soreness effect: serious heterogeneity, wide uncertainty in the effect and methodological limitations of included trials. The number 68 is the sum of publication Ns, not confirmed unique participants; review time points are described inconsistently.

A review of four assessments of post-exercise soreness found a reduction on average: SMD −1.33 (95% CI −2.57…−0.09), p=0.03, I²=87%. Heterogeneity was high, and participant independence was not confirmed.

Study findings. A review of four assessments of post-exercise soreness found a reduction on average: SMD −1.33 (95% CI −2.57…−0.09), p=0.03, I²=87%. Heterogeneity was high, and participant independence was not confirmed.

Studied regimen1000 mg quercetin/day or 1000 mg oncequercetin preparations studied
Duration and population14 days or once 3 hours before exerciseYoung participants after intense exercise; a total of 68 participants across four publications, possible overlap was not checked

Comparison with control

days with symptoms3/4 ModerateRead moreCollapse
Confidence
3/4 ModerateModerate confidence: the numbers of days with symptoms were similar between groups, but comparison precision leaves uncertainty about a small change in sick days. Questionnaire analysis covered 947 participants; 1002 completed the study. The conclusion concerns the combination, not quercetin alone.

Community adults; 1002 study completers, symptom analysis 315/315/317. days with symptoms: 8.5±0.5 and 8.5±0.5 versus 8.4±0.5 days, p=0.982; mean ± SEM. The result applies to the combination, not to quercetin alone.

Study findings. Community adults; 1002 study completers, symptom analysis 315/315/317. days with symptoms: 8.5±0.5 and 8.5±0.5 versus 8.4±0.5 days, p=0.982; mean ± SEM. The result applies to the combination, not to quercetin alone.

Studied regimenquercetin 500 mg + vitamin C 500 mg + niacin 20 mg per day or quercetin 1000 mg + vitamin C 1000 mg + niacin 40 mg per daychewable tablets: quercetin with vitamin C and niacin
Duration and population12 weeksCommunity adults; 1002 study completers, symptom analysis 315/315/317

Comparison with placebo without the three active ingredients

symptom severity3/4 ModerateRead moreCollapse
Confidence
3/4 ModerateModerate confidence: no clear difference in total severity over 12 weeks was established. The data still allow differences in cumulative symptom burden. This is an analysis of questionnaires from 947 participants for the combination of quercetin, vitamin C and niacin.

Community adults; 1002 study completers, symptom analysis 315/315/317. symptom severity: 18.3±1.2 and 19.8±1.3 versus 19.3±1.3 points, p=0.670; mean ± SEM. The result applies to the combination, not to quercetin alone.

Study findings. Community adults; 1002 study completers, symptom analysis 315/315/317. symptom severity: 18.3±1.2 and 19.8±1.3 versus 19.3±1.3 points, p=0.670; mean ± SEM. The result applies to the combination, not to quercetin alone.

Studied regimenquercetin 500 mg + vitamin C 500 mg + niacin 20 mg per day or quercetin 1000 mg + vitamin C 1000 mg + niacin 40 mg per daychewable tablets: quercetin with vitamin C and niacin
Duration and population12 weeksCommunity adults; 1002 study completers, symptom analysis 315/315/317

Comparison with placebo without the three active ingredients

total symptom score3/4 ModerateRead moreCollapse
Confidence
3/4 ModerateModerate confidence: total symptom scores were similar, but precision of the questionnaire analysis of 947 participants leaves uncertainty about the magnitude of a possible change. Statistical non-significance does not prove equality. The conclusion concerns the combination.

Community adults; 1002 study completers, symptom analysis 315/315/317. total symptom score: 108±8.3 and 111±8.0 versus 108±8.0 points, p=0.946; mean ± SEM. The result applies to the combination, not to quercetin alone.

Study findings. Community adults; 1002 study completers, symptom analysis 315/315/317. total symptom score: 108±8.3 and 111±8.0 versus 108±8.0 points, p=0.946; mean ± SEM. The result applies to the combination, not to quercetin alone.

Studied regimenquercetin 500 mg + vitamin C 500 mg + niacin 20 mg per day or quercetin 1000 mg + vitamin C 1000 mg + niacin 40 mg per daychewable tablets: quercetin with vitamin C and niacin
Duration and population12 weeksCommunity adults; 1002 study completers, symptom analysis 315/315/317

Comparison with placebo without the three active ingredients

JRQLQ total score2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison of JRQLQ total score for the specified phytosomal form: limited sample and variability, lack of adjustment for numerous measures and per-protocol analysis limit the assessment. Final total score p=0.04, but change from baseline p=0.13; these comparisons are not equivalent.

Adults in Japan with hay fever symptoms; analysis 30/30. JRQLQ total score: At the end 19.1±12.1 versus 26.3±15.0, p=0.04; change −15.6±17.5 versus −8.4±18.5, p=0.13. Mean ± SD. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment.

Study findings. Adults in Japan with hay fever symptoms; analysis 30/30. JRQLQ total score: At the end 19.1±12.1 versus 26.3±15.0, p=0.04; change −15.6±17.5 versus −8.4±18.5, p=0.13. Mean ± SD. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment.

Studied regimen200 mg of quercetin itself per day in phytosomal form: four tablets containing 50 mg quercetin each, two with breakfast and two with dinnerphytosomal quercetin
Duration and population4 weeksAdults with mild nose and eye complaints were included; analysis 30/30. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed.

Comparison with placebo

combined nose and eye symptoms2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison of total nasal and eye symptoms for the specified phytosomal form: limited sample and variability, lack of adjustment for numerous measures and per-protocol analysis limit the assessment. Change in the sum of nasal/eye symptoms p=0.44; lack of significance does not establish equivalence.

Adults in Japan with hay fever symptoms; analysis 30/30. combined nose and eye symptoms: Change −2.6±5.1 versus −1.6±5.3, p=0.44. Mean ± SD. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment.

Study findings. Adults in Japan with hay fever symptoms; analysis 30/30. combined nose and eye symptoms: Change −2.6±5.1 versus −1.6±5.3, p=0.44. Mean ± SD. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment.

Studied regimen200 mg of quercetin itself per day in phytosomal form: four tablets containing 50 mg quercetin each, two with breakfast and two with dinnerphytosomal quercetin
Duration and population4 weeksAdults with mild nose and eye complaints were included; analysis 30/30. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed.

Comparison with placebo

JRQLQ quality of life2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison of JRQLQ quality of life for the specified phytosomal form: limited sample and variability, lack of adjustment for numerous measures and per-protocol analysis limit the assessment. Final QOL p=0.02, but comparative change p=0.10; the final result does not replace a comparison of changes.

Adults in Japan with hay fever symptoms; analysis 30/30. JRQLQ quality of life: At the end 11.6±9.1 versus 17.6±11.4, p=0.02; change −12.9±13.8 versus −6.8±14.1, p=0.10. Mean ± SD. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment.

Study findings. Adults in Japan with hay fever symptoms; analysis 30/30. JRQLQ quality of life: At the end 11.6±9.1 versus 17.6±11.4, p=0.02; change −12.9±13.8 versus −6.8±14.1, p=0.10. Mean ± SD. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment.

Studied regimen200 mg of quercetin itself per day in phytosomal form: four tablets containing 50 mg quercetin each, two with breakfast and two with dinnerphytosomal quercetin
Duration and population4 weeksAdults with mild nose and eye complaints were included; analysis 30/30. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed.

Comparison with placebo

JRQLQ sleep item2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison of JRQLQ sleep item for the specified phytosomal form: limited sample and variability, lack of adjustment for numerous measures and per-protocol analysis limit the assessment. The printed p=0.00 is a rounded value, not an exact zero.

Adults in Japan with hay fever symptoms; analysis 30/30. JRQLQ sleep item: Change −1.0±0.9 versus −0.1±1.0; the source rounds p to 0.00. Mean ± SD. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment.

Study findings. Adults in Japan with hay fever symptoms; analysis 30/30. JRQLQ sleep item: Change −1.0±0.9 versus −0.1±1.0; the source rounds p to 0.00. Mean ± SD. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment.

Studied regimen200 mg of quercetin itself per day in phytosomal form: four tablets containing 50 mg quercetin each, two with breakfast and two with dinnerphytosomal quercetin
Duration and population4 weeksAdults with mild nose and eye complaints were included; analysis 30/30. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed.

Comparison with placebo

physical symptoms (JRQLQ domain)2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison of physical symptoms (JRQLQ domain) for the specified phytosomal form: limited sample and variability, lack of adjustment for numerous measures and per-protocol analysis limit the assessment. The physical domain is part of one questionnaire, not a separate trial; p=0.03 for change.

Adults in Japan with hay fever symptoms; analysis 30/30. physical symptoms (JRQLQ domain): Change −2.1±1.8 versus −1.0±2.0, p=0.03. Mean ± SD. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment.

Study findings. Adults in Japan with hay fever symptoms; analysis 30/30. physical symptoms (JRQLQ domain): Change −2.1±1.8 versus −1.0±2.0, p=0.03. Mean ± SD. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment.

Studied regimen200 mg of quercetin itself per day in phytosomal form: four tablets containing 50 mg quercetin each, two with breakfast and two with dinnerphytosomal quercetin
Duration and population4 weeksAdults with mild nose and eye complaints were included; analysis 30/30. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed.

Comparison with placebo

JRQLQ sneezing at week 42/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison of JRQLQ sneezing at week 4 for the specified phytosomal form: limited sample and variability, lack of adjustment for numerous measures and per-protocol analysis limit the assessment. Sneezing in Table III is a final median and interquartile range at week 4, not mean±SD or a change; the different rhinitis scale in Table IV has different baseline levels and does not substitute for JRQLQ here.

Adults in Japan with hay fever symptoms; analysis 30/30. JRQLQ sneezing at week 4: Median (Q1–Q3): 1.0 (1.0–2.0) versus 1.5 (1.0–2.0), p=0.04. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment.

Study findings. Adults in Japan with hay fever symptoms; analysis 30/30. JRQLQ sneezing at week 4: Median (Q1–Q3): 1.0 (1.0–2.0) versus 1.5 (1.0–2.0), p=0.04. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment.

Studied regimen200 mg of quercetin itself per day in phytosomal form: four tablets containing 50 mg quercetin each, two with breakfast and two with dinnerphytosomal quercetin
Duration and population4 weeksAdults with mild nose and eye complaints were included; analysis 30/30. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed.

Comparison with placebo

JRQLQ nasal discharge at week 42/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison of JRQLQ nasal discharge at week 4 for the studied phytosomal form: per-protocol analysis and many unadjusted comparisons, together with a small sample and the distribution of ordinal measures, limit the conclusion. JRQLQ nasal discharge: medians at week 4 are equal, but IQRs are not; p=0.23 does not establish equivalence.

Adults in Japan with hay fever symptoms; analysis 30/30. JRQLQ nasal discharge at week 4: Median (Q1–Q3): 1.0 (1.0–1.0) versus 1.0 (1.0–2.0), p=0.23. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment.

Study findings. Adults in Japan with hay fever symptoms; analysis 30/30. JRQLQ nasal discharge at week 4: Median (Q1–Q3): 1.0 (1.0–1.0) versus 1.0 (1.0–2.0), p=0.23. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment.

Studied regimen200 mg of quercetin itself per day in phytosomal form: four tablets containing 50 mg quercetin each, two with breakfast and two with dinnerphytosomal quercetin
Duration and population4 weeksAdults with mild nose and eye complaints were included; analysis 30/30. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed.

Comparison with placebo

JRQLQ itchy eyes at week 42/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison of JRQLQ eye itching at week 4 for the studied phytosomal form: per-protocol analysis and many unadjusted comparisons, together with a small sample and the distribution of ordinal measures, limit the conclusion. JRQLQ eye itching: week 4 p=0.55; this is a separate scale from the rhinitis scale and is not a comparison of change.

Adults in Japan with hay fever symptoms; analysis 30/30. JRQLQ itchy eyes at week 4: Median (Q1–Q3): 1.5 (1.0–2.0) versus 2.0 (1.0–2.0), p=0.55. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment.

Study findings. Adults in Japan with hay fever symptoms; analysis 30/30. JRQLQ itchy eyes at week 4: Median (Q1–Q3): 1.5 (1.0–2.0) versus 2.0 (1.0–2.0), p=0.55. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment.

Studied regimen200 mg of quercetin itself per day in phytosomal form: four tablets containing 50 mg quercetin each, two with breakfast and two with dinnerphytosomal quercetin
Duration and population4 weeksAdults with mild nose and eye complaints were included; analysis 30/30. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed.

Comparison with placebo

sneezing on the rhinitis scale at week 42/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison of rhinitis-scale sneezing at week 4 for the studied phytosomal form: per-protocol analysis and many unadjusted comparisons, together with a small sample and the distribution of ordinal measures, limit the conclusion. Rhinitis-scale sneezing: before intervention medians 1 versus 2 and p=0.04, and at week 4 p=0.01; without comparative analysis of change the final difference does not prove additional improvement.

Adults in Japan with hay fever symptoms; analysis 30/30. sneezing on the rhinitis scale at week 4: Median (Q1–Q3): 1.0 (1.0–1.0) versus 1.0 (1.0–2.0), p=0.01. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment. This is a comparison of final scores: symptoms were already milder in the quercetin group before supplementation (p=0.04), so it does not show additional improvement.

Study findings. Adults in Japan with hay fever symptoms; analysis 30/30. sneezing on the rhinitis scale at week 4: Median (Q1–Q3): 1.0 (1.0–1.0) versus 1.0 (1.0–2.0), p=0.01. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment. This is a comparison of final scores: symptoms were already milder in the quercetin group before supplementation (p=0.04), so it does not show additional improvement.

Studied regimen200 mg of quercetin itself per day in phytosomal form: four tablets containing 50 mg quercetin each, two with breakfast and two with dinnerphytosomal quercetin
Duration and population4 weeksAdults with mild nose and eye complaints were included; analysis 30/30. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed.

Comparison with placebo

Runny nose on the rhinitis scale at week 42/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison of rhinitis-scale rhinorrhea at week 4 for the studied phytosomal form: per-protocol analysis and many unadjusted comparisons, together with a small sample and the distribution of ordinal measures, limit the conclusion. Rhinitis-scale rhinorrhea: before intervention medians 1 versus 2 and p=0.04, and at week 4 p=0.01; additional improvement versus placebo is not established.

Adults in Japan with hay fever symptoms; analysis 30/30. rhinorrhea on the rhinitis scale at week 4: Median (Q1–Q3): 1.0 (1.0–1.0) versus 1.5 (1.0–2.0), p=0.01. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment. This is a comparison of final scores: symptoms were already milder in the quercetin group before supplementation (p=0.04), so it does not show additional improvement.

Study findings. Adults in Japan with hay fever symptoms; analysis 30/30. rhinorrhea on the rhinitis scale at week 4: Median (Q1–Q3): 1.0 (1.0–1.0) versus 1.5 (1.0–2.0), p=0.01. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment. This is a comparison of final scores: symptoms were already milder in the quercetin group before supplementation (p=0.04), so it does not show additional improvement.

Studied regimen200 mg of quercetin itself per day in phytosomal form: four tablets containing 50 mg quercetin each, two with breakfast and two with dinnerphytosomal quercetin
Duration and population4 weeksAdults with mild nose and eye complaints were included; analysis 30/30. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed.

Comparison with placebo

itchy eyes on the rhinitis scale at week 12/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison of rhinitis-scale eye itching at week 1 for the studied phytosomal form: per-protocol analysis and many unadjusted comparisons, together with a small sample and the distribution of ordinal measures, limit the conclusion. Rhinitis-scale eye itching: week 1 p=0.02, week 4 p=0.22; these are different time points and not JRQLQ. The week 1 effect should not be transferred to week 4.

Adults in Japan with hay fever symptoms; analysis 30/30. itchy eyes on the rhinitis scale at week 1: Median (Q1–Q3): 1.0 (1.0–2.0) versus 2.0 (1.0–2.0), p=0.02; at week 4 p=0.22. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment.

Study findings. Adults in Japan with hay fever symptoms; analysis 30/30. itchy eyes on the rhinitis scale at week 1: Median (Q1–Q3): 1.0 (1.0–2.0) versus 2.0 (1.0–2.0), p=0.02; at week 4 p=0.22. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed; multiple outcomes without adjustment.

Studied regimen200 mg of quercetin itself per day in phytosomal form: four tablets containing 50 mg quercetin each, two with breakfast and two with dinnerphytosomal quercetin
Duration and population4 weeksAdults with mild nose and eye complaints were included; analysis 30/30. Regular use of antiallergic medicines was excluded; occasional use as needed was allowed.

Comparison with placebo

days ill in the exploratory subgroup2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison of the Q1000 combination with placebo in the selected subgroup: the reported result arose among many subgroups in the absence of an overall effect, and comparative uncertainty and the sizes of the two groups were not reported. An effect cannot be attributed to quercetin alone.

High self-rated physical fitness, age 40 years and older; 325 in total across all groups. days ill in the exploratory subgroup: 31% reduction in days with symptoms versus placebo, p=0.048. Exploratory subgroup of the same trial; group sizes were not reported.

Study findings. High self-rated physical fitness, age 40 years and older; 325 in total across all groups. days ill in the exploratory subgroup: 31% reduction in days with symptoms versus placebo, p=0.048. Exploratory subgroup of the same trial; group sizes were not reported.

Studied regimenquercetin 1000 mg + vitamin C 1000 mg + niacin 40 mg/daychewable tablets: quercetin with vitamin C and niacin
Duration and population12 weeksHigh self-rated physical fitness, age 40 years and older; 325 in total across all groups

Comparison with placebo without the three active ingredients

severity in the exploratory subgroup2/4 LowRead moreCollapse
Confidence
2/4 LowLow confidence in the comparison of the Q1000 combination with placebo in the selected subgroup: the reported result arose among many subgroups in the absence of an overall effect, and comparative uncertainty and the sizes of the two groups were not reported. An effect cannot be attributed to quercetin alone.

High self-rated physical fitness, age 40 years and older; 325 in total across all groups. severity in the exploratory subgroup: 36% reduction in severity versus placebo, p=0.020. Exploratory subgroup of the same trial; group sizes were not reported.

Study findings. High self-rated physical fitness, age 40 years and older; 325 in total across all groups. severity in the exploratory subgroup: 36% reduction in severity versus placebo, p=0.020. Exploratory subgroup of the same trial; group sizes were not reported.

Studied regimenquercetin 1000 mg + vitamin C 1000 mg + niacin 40 mg/daychewable tablets: quercetin with vitamin C and niacin
Duration and population12 weeksHigh self-rated physical fitness, age 40 years and older; 325 in total across all groups

Comparison with placebo without the three active ingredients

Safety and limitations

A review of human studies reported mostly mild adverse events. The authors found insufficient data to assess safety at doses of 1000 mg/day or more for longer than 12 weeks. Pregnant and breastfeeding women and women planning pregnancy did not take part in the 4-week phytosomal quercetin study: these groups were excluded by the protocol. Another 4-week study in 146 children with allergic rhinoconjunctivitis compared a blend of quercetin, perilla and vitamin D3 with placebo; both groups received an antihistamine. No significant adverse events were recorded in the study. These findings apply to specific preparations, groups and observation periods. An analysis of five preparations found that one roughly matched its label, three contained about 80%, and one 14.8%; this sample does not describe the entire market. The review describes animal experiments suggesting a possible worsening of damage in already affected kidneys and stimulation of tumor development, especially estrogen-dependent tumors. These are preclinical signals: they do not establish the frequency or causal risk in humans.

Safety Aspects of the Use of Quercetin as a Dietary Supplement ↗ · Effects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind parallel-group study ↗ · A polycentric, randomized, double blind, parallel-group, placebo-controlled study on Lertal®, a multicomponent nutraceutical, as add-on treatment in children with allergic rhinoconjunctivitis: phase I during active treatment ↗ · The Quercetin Paradox, Evaluation of its Therapeutic Efficacy as a Nutraceutical in Clinical Trials: Evidence and Speculation ↗

Interactions

WithEffectActionSource
fexofenadineIn 12 healthy volunteers, after quercetin 500 mg three times a day for 7 days, the AUC of fexofenadine 60 mg increased by 55% and Cmax by 68%; the clinical significance is unknown.If taking fexofenadine, discuss a quercetin supplement with a doctor or pharmacist before combining them.Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers ↗

Food sources

Five pairs were matched by NDB, state and edible portion; 100 g is a comparison serving, not a recommendation. USDA expresses results as aglycone equivalents, including converted glycosides.

Allium vegetables

Onion contains quercetin; the content depends on the sample and processing.

USDA Database for the Flavonoid Content of Selected Foods, Release 3.3 (2018) ↗

Brassica and leafy vegetables

Kale and broccoli contain quercetin.

USDA Database for the Flavonoid Content of Selected Foods, Release 3.3 (2018) ↗

Fruit

Quercetin is found, for example, in raw apples with skin.

USDA Database for the Flavonoid Content of Selected Foods, Release 3.3 (2018) ↗

Berries

Quercetin is found, for example, in raw cranberries.

USDA Database for the Flavonoid Content of Selected Foods, Release 3.3 (2018) ↗

Food composition

FoodGroupAmountServingCaloriesSources
Onionraw, edible portionVegetables20.3 mg quercetin as aglycone equivalents / 100 g100 g · 20.3 mg quercetin as aglycone equivalents · 40 kcal40 kcal / 100 gUSDA Database for the Flavonoid Content of Selected Foods, Release 3.3 (2018) ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015), Vegetables and Vegetable Products ↗
Kaleraw, edible portionLeafy vegetables22.58 mg quercetin as aglycone equivalents / 100 g100 g · 22.58 mg quercetin as aglycone equivalents · 49 kcal49 kcal / 100 gUSDA Database for the Flavonoid Content of Selected Foods, Release 3.3 (2018) ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015), Vegetables and Vegetable Products ↗
Broccoliraw, edible portionVegetables3.26 mg quercetin as aglycone equivalents / 100 g100 g · 3.26 mg quercetin as aglycone equivalents · 34 kcal34 kcal / 100 gUSDA Database for the Flavonoid Content of Selected Foods, Release 3.3 (2018) ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015), Vegetables and Vegetable Products ↗
Appleraw, with skin, edible portionFruit4.01 mg quercetin as aglycone equivalents / 100 g100 g · 4.01 mg quercetin as aglycone equivalents · 52 kcal52 kcal / 100 gUSDA Database for the Flavonoid Content of Selected Foods, Release 3.3 (2018) ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015), Fruits and Fruit Juices ↗
Cranberryraw, edible portionBerries16.64 mg quercetin as aglycone equivalents / 100 g100 g · 16.64 mg quercetin as aglycone equivalents · 46 kcal46 kcal / 100 gUSDA Database for the Flavonoid Content of Selected Foods, Release 3.3 (2018) ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015), Fruits and Fruit Juices ↗

Studies

PublicationWhat was studiedParticipantsForm and doseResult
Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial ↗randomized controlled trialTwo publications from one trial: Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial (https://pubmed.ncbi.nlm.nih.gov/20478383/); The effects of quercetin supplementation on cognitive functioning in a community sample: a randomized, placebo-controlled trial (https://pubmed.ncbi.nlm.nih.gov/23983966/). CNS Vital Signs cognitive test results days with symptoms: days with symptoms symptom severity: symptom severity total symptom score: total symptom score days ill in the exploratory subgroup: days ill in the exploratory subgroup severity in the exploratory subgroup: severity in the exploratory subgroupCommunity adults; 941 completed, 309/319/313 days with symptoms: Community adults; 1002 study completers, symptom analysis 315/315/317 symptom severity: Community adults; 1002 study completers, symptom analysis 315/315/317 total symptom score: Community adults; 1002 study completers, symptom analysis 315/315/317 days ill in the exploratory subgroup: High self-rated physical fitness, age 40 years and older; 325 in total across all groups severity in the exploratory subgroup: High self-rated physical fitness, age 40 years and older; 325 in total across all groupsquercetin chewable tablets; the linked study describes a combination with vitamin C and niacin; 500 or 1000 mg quercetin/day; 12 weeks; comparison: placebo days with symptoms: chewable tablets: quercetin with vitamin C and niacin; quercetin 500 mg + vitamin C 500 mg + niacin 20 mg per day or quercetin 1000 mg + vitamin C 1000 mg + niacin 40 mg per day; 12 weeks; comparison: placebo without the three active ingredients symptom severity: chewable tablets: quercetin with vitamin C and niacin; quercetin 500 mg + vitamin C 500 mg + niacin 20 mg per day or quercetin 1000 mg + vitamin C 1000 mg + niacin 40 mg per day; 12 weeks; comparison: placebo without the three active ingredients total symptom score: chewable tablets: quercetin with vitamin C and niacin; quercetin 500 mg + vitamin C 500 mg + niacin 20 mg per day or quercetin 1000 mg + vitamin C 1000 mg + niacin 40 mg per day; 12 weeks; comparison: placebo without the three active ingredients days ill in the exploratory subgroup: chewable tablets: quercetin with vitamin C and niacin; quercetin 1000 mg + vitamin C 1000 mg + niacin 40 mg/day; 12 weeks; comparison: placebo without the three active ingredients severity in the exploratory subgroup: chewable tablets: quercetin with vitamin C and niacin; quercetin 1000 mg + vitamin C 1000 mg + niacin 40 mg/day; 12 weeks; comparison: placebo without the three active ingredientsCommunity adults; 941 completed, 309/319/313. CNS Vital Signs cognitive domains: No significant group-by-time interaction was found for memory, attention, psychomotor speed or cognitive flexibility. Means ± SD before and after for each of the six domains are given in the results table. The formulation cannot be regarded as proven monotherapy. days with symptoms: Community adults; 1002 study completers, symptom analysis 315/315/317. days with symptoms: 8.5±0.5 and 8.5±0.5 versus 8.4±0.5 days, p=0.982; mean ± SEM. The result applies to the combination, not to quercetin alone. symptom severity: Community adults; 1002 study completers, symptom analysis 315/315/317. symptom severity: 18.3±1.2 and 19.8±1.3 versus 19.3±1.3 points, p=0.670; mean ± SEM. The result applies to the combination, not to quercetin alone. total symptom score: Community adults; 1002 study completers, symptom analysis 315/315/317. total symptom score: 108±8.3 and 111±8.0 versus 108±8.0 points, p=0.946; mean ± SEM. The result applies to the combination, not to quercetin alone. days ill in the exploratory subgroup: High self-rated physical fitness, age 40 years and older; 325 in total across all groups. days ill in the exploratory subgroup: 31% reduction in days with symptoms versus placebo, p=0.048. Exploratory subgroup of the same trial; group sizes were not reported. severity in the exploratory subgroup: High self-rated physical fitness, age 40 years and older; 325 in total across all groups. severity in the exploratory subgroup: 36% reduction in severity versus placebo, p=0.020. Exploratory subgroup of the same trial; group sizes were not reported.
The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗randomized controlled trialMMSE total cognitive test score, points: MMSE total cognitive test score, points Temporal orientation (MMSE), points: Temporal orientation (MMSE), points Spatial orientation (MMSE), points: Spatial orientation (MMSE), points Registration (MMSE), points: Registration (MMSE), points Attention (MMSE), points: Attention (MMSE), points Recall from memory (MMSE), points: Recall from memory (MMSE), points Naming two objects (MMSE), points: Naming two objects (MMSE), points Repeating a phrase (MMSE), points: Repeating a phrase (MMSE), points Following an instruction (MMSE), points: Following an instruction (MMSE), points Writing a sentence (MMSE), points: Writing a sentence (MMSE), points Reading and following an instruction (MMSE), points: Reading and following an instruction (MMSE), points Copying a drawing (MMSE), points: Copying a drawing (MMSE), points CADi2 total score, points: CADi2 total score, points CADi2 completion time, seconds: CADi2 completion time, seconds Low mood (Self-rating Depression Scale, SDS), points: Low mood (Self-rating Depression Scale, SDS), points Apathy — indifference (Apathy Scale), points: Apathy — indifference (Apathy Scale), points Word recall (separate test), points: Word recall (separate test), pointsMMSE total cognitive test score, points: Healthy older people; analysis 28/33 Temporal orientation (MMSE), points: Healthy older people; analysis 28/33 Spatial orientation (MMSE), points: Healthy older people; analysis 28/33 Registration (MMSE), points: Healthy older people; analysis 28/33 Attention (MMSE), points: Healthy older people; analysis 28/33 Recall from memory (MMSE), points: Healthy older people; analysis 28/33 Naming two objects (MMSE), points: Healthy older people; analysis 28/33 Repeating a phrase (MMSE), points: Healthy older people; analysis 28/33 Following an instruction (MMSE), points: Healthy older people; analysis 28/33 Writing a sentence (MMSE), points: Healthy older people; analysis 28/33 Reading and following an instruction (MMSE), points: Healthy older people; analysis 28/33 Copying a drawing (MMSE), points: Healthy older people; analysis 28/33 CADi2 total score, points: Healthy older people; analysis 28/33 CADi2 completion time, seconds: Healthy older people; analysis 28/33 Low mood (Self-rating Depression Scale, SDS), points: Healthy older people; analysis 28/33 Apathy — indifference (Apathy Scale), points: Healthy older people; analysis 28/33 Word recall (separate test), points: Healthy older people; analysis 28/33MMSE total cognitive test score, points: Sarasara Gold onion powder; 11 g/day, about 50 mg quercetin aglycone equivalents; 24 weeks; comparison: white onion powder without quercetin Temporal orientation (MMSE), points: Sarasara Gold onion powder; 11 g/day, about 50 mg quercetin aglycone equivalents; 24 weeks; comparison: white onion powder without quercetin Spatial orientation (MMSE), points: Sarasara Gold onion powder; 11 g/day, about 50 mg quercetin aglycone equivalents; 24 weeks; comparison: white onion powder without quercetin Registration (MMSE), points: Sarasara Gold onion powder; 11 g/day, about 50 mg quercetin aglycone equivalents; 24 weeks; comparison: white onion powder without quercetin Attention (MMSE), points: Sarasara Gold onion powder; 11 g/day, about 50 mg quercetin aglycone equivalents; 24 weeks; comparison: white onion powder without quercetin Recall from memory (MMSE), points: Sarasara Gold onion powder; 11 g/day, about 50 mg quercetin aglycone equivalents; 24 weeks; comparison: white onion powder without quercetin Naming two objects (MMSE), points: Sarasara Gold onion powder; 11 g/day, about 50 mg quercetin aglycone equivalents; 24 weeks; comparison: white onion powder without quercetin Repeating a phrase (MMSE), points: Sarasara Gold onion powder; 11 g/day, about 50 mg quercetin aglycone equivalents; 24 weeks; comparison: white onion powder without quercetin Following an instruction (MMSE), points: Sarasara Gold onion powder; 11 g/day, about 50 mg quercetin aglycone equivalents; 24 weeks; comparison: white onion powder without quercetin Writing a sentence (MMSE), points: Sarasara Gold onion powder; 11 g/day, about 50 mg quercetin aglycone equivalents; 24 weeks; comparison: white onion powder without quercetin Reading and following an instruction (MMSE), points: Sarasara Gold onion powder; 11 g/day, about 50 mg quercetin aglycone equivalents; 24 weeks; comparison: white onion powder without quercetin Copying a drawing (MMSE), points: Sarasara Gold onion powder; 11 g/day, about 50 mg quercetin aglycone equivalents; 24 weeks; comparison: white onion powder without quercetin CADi2 total score, points: Sarasara Gold onion powder; 11 g/day, about 50 mg quercetin aglycone equivalents; 24 weeks; comparison: white onion powder without quercetin CADi2 completion time, seconds: Sarasara Gold onion powder; 11 g/day, about 50 mg quercetin aglycone equivalents; 24 weeks; comparison: white onion powder without quercetin Low mood (Self-rating Depression Scale, SDS), points: Sarasara Gold onion powder; 11 g/day, about 50 mg quercetin aglycone equivalents; 24 weeks; comparison: white onion powder without quercetin Apathy — indifference (Apathy Scale), points: Sarasara Gold onion powder; 11 g/day, about 50 mg quercetin aglycone equivalents; 24 weeks; comparison: white onion powder without quercetin Word recall (separate test), points: Sarasara Gold onion powder; 11 g/day, about 50 mg quercetin aglycone equivalents; 24 weeks; comparison: white onion powder without quercetinMMSE total cognitive test score, points: Healthy older people; analysis 28/33. MMSE Sum score (score): At baseline 27.1 ± 1.5 versus 27.5 ± 1.4; change over 24 weeks 1.7 ± 1.9 versus 0.9 ± 1.7, p=0.024*; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin. Temporal orientation (MMSE), points: Healthy older people; analysis 28/33. MMSE Temporal orientation (score): At baseline 4.9 ± 0.3 versus 5.0 ± 0.0; change over 24 weeks 0.1 ± 0.3 versus 0.0 ± 0.2, p=0.046*; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin. Spatial orientation (MMSE), points: Healthy older people; analysis 28/33. MMSE Spatial orientation (score): At baseline 4.4 ± 0.7 versus 4.0 ± 0.8; change over 24 weeks 0.4 ± 0.9 versus 0.6 ± 0.9, p=0.446; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin. Registration (MMSE), points: Healthy older people; analysis 28/33. MMSE Registration (score): At baseline 2.9 ± 0.6 versus 3.0 ± 0.0; change over 24 weeks 0.1 ± 0.6 versus 0.0 ± 0.0, p=0.212; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin. Attention (MMSE), points: Healthy older people; analysis 28/33. MMSE Attention (score): At baseline 4.0 ± 0.9 versus 4.2 ± 1.0; change over 24 weeks 0.6 ± 1.2 versus 0.3 ± 1.0, p=0.286; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin. Recall from memory (MMSE), points: Healthy older people; analysis 28/33. MMSE Remote memory (score): At baseline 2.7 ± 0.5 versus 2.8 ± 0.5; change over 24 weeks 0.3 ± 0.6 versus 0.1 ± 0.6, p=0.292; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin. Naming two objects (MMSE), points: Healthy older people; analysis 28/33. MMSE Naming two objects (score): At baseline 2.0 ± 0.0 versus 2.0 ± 0.0; change over 24 weeks 0.0 ± 0.0 versus 0.0 ± 0.0, p=1.000; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin. Repeating a phrase (MMSE), points: Healthy older people; analysis 28/33. MMSE Repeat (score): At baseline 0.8 ± 0.4 versus 1.0 ± 0.0; change over 24 weeks 0.0 ± 0.4 versus −0.1 ± 0.2, p=0.275; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin. Following an instruction (MMSE), points: Healthy older people; analysis 28/33. MMSE Stage command (score): At baseline 2.8 ± 0.4 versus 2.6 ± 0.6; change over 24 weeks 0.1 ± 0.6 versus 0.2 ± 0.7, p=0.821; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin. Writing a sentence (MMSE), points: Healthy older people; analysis 28/33. MMSE Writing a complete sentence (score): At baseline 1.0 ± 0.2 versus 1.0 ± 0.0; change over 24 weeks 0.0 ± 0.3 versus 0.0 ± 0.2, p=0.601; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin. Reading and following an instruction (MMSE), points: Healthy older people; analysis 28/33. MMSE Reading and obey (score): At baseline 0.9 ± 0.4 versus 0.9 ± 0.3; change over 24 weeks −0.1 ± 0.4 versus −0.1 ± 0.3, p=0.859; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin. Copying a drawing (MMSE), points: Healthy older people; analysis 28/33. MMSE Copy the diagram (score): At baseline 0.9 ± 0.4 versus 1.0 ± 0.2; change over 24 weeks 0.1 ± 0.4 versus −0.1 ± 0.2, p=0.067; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin. CADi2 total score, points: Healthy older people; analysis 28/33. CADi2 total score (score): At baseline 9.3 ± 1.0 versus 8.8 ± 1.0; change over 24 weeks 0.0 ± 0.9 versus 0.2 ± 1.0, p=0.262; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin. CADi2 completion time, seconds: Healthy older people; analysis 28/33. CADi2 total response time (s): At baseline 98.9 ± 34.8 versus 94.5 ± 22.1; change over 24 weeks −11.9 ± 33.4 versus −7.3 ± 21.5, p=0.728; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin. Low mood (Self-rating Depression Scale, SDS), points: Healthy older people; analysis 28/33. Self-rating Depression Scale (score): At baseline 32.5 ± 7.7 versus 33.1 ± 5.9; change over 24 weeks −2.4 ± 5.0 versus −0.1 ± 4.9, p=0.020*; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin. Apathy — indifference (Apathy Scale), points: Healthy older people; analysis 28/33. Apathy Scale (score): At baseline 6.4 ± 4.8 versus 4.8 ± 4.1; change over 24 weeks −2.6 ± 3.8 versus −0.1 ± 3.0, p=0.021*; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin. Word recall (separate test), points: Healthy older people; analysis 28/33. Verbal recall test (score): At baseline 9.6 ± 2.5 versus 10.2 ± 1.8; change over 24 weeks 1.8 ± 3.1 versus 1.2 ± 2.2, p=0.640; mean ± SD. A result for a particular onion product; multiple measures, not proof of an effect of isolated quercetin.

Sources

Sources
  1. The effects of quercetin supplementation on cognitive functioning in a community sample: a randomized, placebo-controlled trial ↗
  2. The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial ↗
  3. Quercetin supplementation promotes recovery after exercise-induced muscle damage: a systematic review and meta-analysis of randomized controlled trials ↗
  4. Improving quercetin bioavailability: A systematic review and meta-analysis of human intervention studies ↗
  5. Safety Aspects of the Use of Quercetin as a Dietary Supplement ↗
  6. Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers ↗
  7. Effects of repeated oral intake of a quercetin-containing supplement on allergic reaction: a randomized, placebo-controlled, double-blind parallel-group study ↗
  8. A polycentric, randomized, double blind, parallel-group, placebo-controlled study on Lertal®, a multicomponent nutraceutical, as add-on treatment in children with allergic rhinoconjunctivitis: phase I during active treatment ↗
  9. The Quercetin Paradox, Evaluation of its Therapeutic Efficacy as a Nutraceutical in Clinical Trials: Evidence and Speculation ↗
  10. Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial ↗
  11. USDA Database for the Flavonoid Content of Selected Foods, Release 3.3 (2018) ↗
  12. USDA National Nutrient Database for Standard Reference, Release 28 (2015), Vegetables and Vegetable Products ↗
  13. USDA National Nutrient Database for Standard Reference, Release 28 (2015), Fruits and Fruit Juices ↗